{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:15:08Z","timestamp":1783358108227,"version":"3.54.6"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clinme.2026.100582","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:27:47Z","timestamp":1775579267000},"page":"100582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pitfalls in the pharmacotherapy of hypertension"],"prefix":"10.1016","volume":"26","author":[{"given":"Ryan J.","family":"McNally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-750X","authenticated-orcid":false,"given":"Maisarah","family":"Amran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5486-9145","authenticated-orcid":false,"given":"Albert","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Maniero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6899","authenticated-orcid":false,"given":"Luca","family":"Faconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinme.2026.100582_bib1","unstructured":"British Heart Foundation Health Analytics Team. UK cardiovascular disease factsheet. British Heart Foundation; 2026.\u00a0\u3008https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-cvd-statistics-uk-factsheet-jan26.pdf?hash=836271B8610F86FF345146CAD695D6CA&rev=26534e1487094dbd806277891baef112\u3009\u00a0Accessed December 17, 2025."},{"key":"10.1016\/j.clinme.2026.100582_bib2","unstructured":"National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management (NG136). NICE; 2019. Last updated November 21, 2023. \u3008https:\/\/www.nice.org.uk\/guidance\/ng136\u3009 Accessed December 17, 2025."},{"issue":"1","key":"10.1016\/j.clinme.2026.100582_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11586670-000000000-00000","article-title":"The correct administration of antihypertensive drugs according to the principles of clinical pharmacology","volume":"11","author":"Taddei","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.clinme.2026.100582_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41371-023-00882-2","article-title":"Adult hypertension referral pathway and therapeutic management: British and Irish Hypertension Society position statement","volume":"38","author":"Lewis","year":"2024","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10.1016\/j.clinme.2026.100582_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11739-016-1422-x","article-title":"Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity","volume":"11","author":"Brewster","year":"2016","journal-title":"Intern Emerg Med"},{"issue":"23","key":"10.1016\/j.clinme.2026.100582_bib6","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.clinme.2026.100582_bib7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(98)00423-9","article-title":"Rationale and design of the International Verapamil SR\/Trandolapril Study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension","volume":"32","author":"Pepine","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"9227","key":"10.1016\/j.clinme.2026.100582_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clinme.2026.100582_bib9","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1901113","article-title":"Comparison of dual therapies for lowering blood pressure in Black Africans","volume":"380","author":"Ojji","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinme.2026.100582_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ahj.2018.05.006","volume":"204","author":"Mukhtar","year":"2018","journal-title":"Am Heart J"},{"issue":"7551","key":"10.1016\/j.clinme.2026.100582_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.clinme.2026.100582_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"Stone","year":"2017","journal-title":"Immunol Allergy Clin N\u00a0Am"},{"issue":"5","key":"10.1016\/j.clinme.2026.100582_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jch.14436","article-title":"Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis","volume":"24","author":"Liang","year":"2022","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1016\/j.clinme.2026.100582_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","article-title":"Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema","volume":"124","author":"Makani","year":"2011","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.clinme.2026.100582_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/jispcd.JISPCD_57_22","article-title":"Calcium channel blockers induced gingival overgrowth: a comprehensive review from a dental perspective","volume":"12","author":"Damdoum","year":"2022","journal-title":"J Int Soc Prev Community Dent"},{"issue":"12","key":"10.1016\/j.clinme.2026.100582_bib16","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1111\/bcp.14109","article-title":"A review of the prescribing trend of thiazide-type and thiazide-like diuretics in hypertension: a UK perspective","volume":"85","author":"McNally","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"27","key":"10.1016\/j.clinme.2026.100582_bib17","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clinme.2026.100582_bib18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive Black and Nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.clinme.2026.100582_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41371-019-0190-2","article-title":"Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society","volume":"33","author":"Faconti","year":"2019","journal-title":"J Hum Hypertens"},{"issue":"26","key":"10.1016\/j.clinme.2026.100582_bib20","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events","volume":"387","author":"Ishani","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182600031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147021182600031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:22:29Z","timestamp":1783354949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147021182600031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S147021182600031X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100582","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pitfalls in the pharmacotherapy of hypertension","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2026.100582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100582"}}